So we asked over 100 patients to reflect on their decision to accept adjuvant therapy a year down the line. The patients, on the whole, decision regret was fairly low, but the patients that were most likely to regret it with the highest scores were those patients that had a long-term toxicity. We looked at whether CTCAE grading was associated with decision regret, and it wasn’t...
So we asked over 100 patients to reflect on their decision to accept adjuvant therapy a year down the line. The patients, on the whole, decision regret was fairly low, but the patients that were most likely to regret it with the highest scores were those patients that had a long-term toxicity. We looked at whether CTCAE grading was associated with decision regret, and it wasn’t. And also, interestingly, disease recurrence wasn’t associated with regret. Patients would often tell me that they were glad they’d given it a go, even though their cancer had come back. So to summarize, it’s this long-term toxicity, these life-changing effects that do seem to be most associated with regret. And it really, again, highlights the importance of making sure our patients are as well-informed as possible.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
